Cytokinetics Inc (CYTK) SEC filings

CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30

$56.13−0.03 (-0.05%)

Close on Nov 13, 2026Market cap $7.80BP/E –Yield –

SEC filings

40 of Cytokinetics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 4, 2026	SEC EDGAR
Current report	8-K	Nov 4, 2026	Nov 4, 2026	SEC EDGAR
Current report	8-K	Aug 28, 2026	Aug 28, 2026	SEC EDGAR
Current report	8-K	Aug 13, 2026	Aug 13, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Aug 6, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	May 27, 2026	May 27, 2026	SEC EDGAR
Current report	8-K	May 6, 2026	May 8, 2026	SEC EDGAR
Current report	8-K	May 5, 2026	May 5, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 5, 2026	SEC EDGAR
Current report	8-K	May 5, 2026	May 5, 2026	SEC EDGAR
Proxy statement	DEF 14A	May 27, 2026	Apr 17, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 26, 2026	SEC EDGAR
Current report	8-K	Feb 24, 2026	Feb 24, 2026	SEC EDGAR
Current report	8-K	Feb 17, 2026	Feb 17, 2026	SEC EDGAR
Current report	8-K	Dec 19, 2025	Dec 19, 2025	SEC EDGAR
Current report	8-K	Dec 12, 2025	Dec 12, 2025	SEC EDGAR
Current report	8-K	Nov 13, 2025	Nov 14, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 5, 2025	SEC EDGAR
Current report	8-K	Nov 5, 2025	Nov 5, 2025	SEC EDGAR
Current report	8-K	Sep 16, 2025	Sep 22, 2025	SEC EDGAR
Current report	8-K	Sep 15, 2025	Sep 16, 2025	SEC EDGAR
Current report	8-K	Aug 31, 2025	Sep 3, 2025	SEC EDGAR
Current report	8-K	Aug 30, 2025	Sep 2, 2025	SEC EDGAR
Current report	8-K	Aug 19, 2025	Aug 20, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	May 14, 2025	May 16, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 6, 2025	SEC EDGAR
Current report	8-K	May 6, 2025	May 6, 2025	SEC EDGAR
Current report	8-K	Apr 29, 2025	May 1, 2025	SEC EDGAR
Proxy statement	DEF 14A	May 14, 2025	Apr 10, 2025	SEC EDGAR
Current report	8-K	Mar 10, 2025	Mar 10, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Feb 27, 2025	SEC EDGAR
Current report	8-K	Feb 27, 2025	Feb 27, 2025	SEC EDGAR
Current report	8-K	Feb 10, 2025	Feb 11, 2025	SEC EDGAR
Current report	8-K	Dec 16, 2024	Dec 16, 2024	SEC EDGAR
Current report	8-K	Nov 18, 2024	Nov 19, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 7, 2024	SEC EDGAR
Current report	8-K	Nov 1, 2024	Nov 7, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Cytokinetics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-6 reverse split on Jun 25, 2013
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CYTK.

Compare: CYTK vs GYRE · CYTK vs AGIO · CYTK vs GOSS · CYTK vs AKBA · CYTK vs FHTX

Revenue growth29.9% · median 78.0%

Operating margin-625.2% · median -15.7%

Net margin-686.6% · median -33.9%

Company	Revenue	Growth
AKBA	$197.20M	-12.4%
AGIO	$140.84M	+214.4%
CYTK	$113.29M	+29.9%
FHTX	$112.13M	+357.3%
GYRE	$108.15M	-3.7%
GOSS	$78.42M	+78.0%

Company

Next earnings (est.): Feb 23, 2027, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 673
Held by institutions: 100.0%
Auditor: Ernst & Young LLP
SEC CIK: 1061983

Advertisement
300 × 250

See a number that looks wrong?